Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of PTG-300 Regimens in Healthy Volunteers
NCT04516382Phase 1Completed
- Sponsor
- Protagonist Therapeutics, Inc.
- Start
- Sep 2020
- Primary completion
- Jan 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of rusfertide in polycythemia vera (PV) (4 arms), sponsored by Protagonist Therapeutics, Inc. Primary endpoint: Bioavailability of PTG-300 at Week 1. Started Sep 2020; status: completed.
02
Drugs
rusfertide
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT04516382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04516382.